skip to primary navigationskip to content

Sildenafil therapy for fetal cardiovascular dysfunction during hypoxic development: studies in the chick embryo

last modified Dec 12, 2016 11:37 AM
The study published in the Journal of Physiology suggests that sildenafil is a good candidate for human therapy to protect the chronically hypoxic fetus in adverse pregnancy

The research was authored by Nozomi Itani, Katie L. Skeffington, Christian Beck and Dino Giussani.

The work tested the effect of sildenafil (the active ingredient of the well-known drug: Viagra) on treating development affected by chronic hypoxia, using the chick embryo model. Sildenafil is already being tested clinically on women whose pregnancy is complicated by fetal growth restriction, and this study aimed to extend our knowledge on potential direct effects of sildenafil on fetal development.

DOI: 10.1113/JP273393


Filed under: